Abstract: A method of treating obstructive sleep apnea according to this disclosure may include: providing an implant comprising a substantially planar central body portion having a top side and a bottom side; at least two adjustable wing portions; and at least two connecting members, each one of the at least two connecting members extending from opposite sides of the central body portion, the each one of the at least two connecting members being configured for flexibly connecting each one of the at least two wing portions at opposite sides to said central body portion; forming a surgical opening to expose a genioglossus muscle; exposing a branch of a hypoglossal nerve for stimulation by the implant at least on one side of the geniouglossus; forming at least one pocket on at least one side of the geniouglossus; such that the pocket dimensions are configured to fit the at least one of the at least two wing portions of the device; inserting an implant device through the surgical opening such that the central body extends

Abstract: Glaucoma can be treated by implanting an intraocular shunt into an eye. The eye has an anterior chamber and sclera. A shunt can be placed into the eye to establish fluid communication from the anterior chamber of the eye through the sclera. Further, a pharmaceutical or biological agent can be administered to the eye.

Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: The present invention provides a composting toilet (1) including: a body (10), a solids collection chamber (3) for receiving faecal matter, and an agitator (30) for moving faecal matter within the solids collection chamber (3); the agitator (30) rotatably mounted about an axis X, and an agitator drive mechanism (40) for driving the agitator; wherein the agitator drive mechanism (40) comprises a handle (50), an extendable drive shaft (60) having a first end (61) and a second end (62), the first end (61) connected to the handle (50) and the second end (62) is connected to the agitator (40); and the handle (50) is moveable from a first stowed position (51) to a second in-use position (52) for driving rotation of the agitator (30).

Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: A handle permits propping of an implement in a substantially vertical orientation within a ground surface includes an elongate handle body and a spike embedded in a gripping end of the elongate handle body, the spike having an exposed axial portion. A compression spring is disposed about the exposed axial portion of the spike and a hollow sleeve is fitted over the compression spring and gripping end. An opening in an upper end of the sleeve permits passage of the exposed portion of the spike. A pin member transversely disposed within the gripping end of the handle body has ends extending into longitudinal slots of the hollow sleeve such that the handle body is movable axially between first and second positions to enable the exposed axial portion of the spike to be advanced through the opening of the hollow sleeve for advancement into the ground surface.

Abstract: Embodiments of the present invention are directed to processes for the production of (R)-3-hydroxybutyl (R)-3-hydroxybyrate. Poly (R)-3-hydroxybyrate is transesterified with an alcohol, to form a first ester portion and a second ester portion. The first ester portion is reduced to the diol to form a diol portion and the diol portion is reacted with the second ester portion to produce (R)-3-hydroxybutyl (R)-3-hydroxybyrate.

Abstract: Disclosed is a system with (a) a microplate comprising a metallic material for heating one or more samples during thermocycling. The microplate comprises one or more barcodes on a side of the microplate. The system may comprise a barcode reader for reading the one or more barcode. The system may also comprise a first temperature block configured to receive the microplate and/ or provide a denaturing temperature to the one or more samples contained in the microplate, during the thermocycling. The system may also comprise a second temperature block configured to receive the microplate and/or provide an extension temperature to the one or more samples contained in the microplate, during the thermocycling. The system may also comprise a conveyor configured to move the microplate between a sensing device, the first temperature block, and the second temperature block, during the thermocycling.

Abstract: Embodiments herein describe a multi-port memory system that includes one or more single port memories (e.g., a memory that can perform only one read or one write at any given time, referred to as a 1W or 1R memory). That is, the multi-port memory system can perform multiple read and writes in parallel (e.g., 1R/1W, 1R/3W, 2R/2W, 3R/1W, etc.) even though the memory in the system can only perform one read or one write at any given time. The advantage of doing so is a reduction in area and power.

Abstract: Expanded graphite and/or vermiculite are introduced into the friction lining mixture to eliminate or substantially reduce the amount of binder present therein. The friction lining at most contains from 2.5% by weight of binder. By omitting/reducing binder, the production is very stable and the friction linings can be easily reproduced. The process steps of hardening (including the hardening furnace) and scorching (including the necessary equipment) can be omitted when making such friction linings.

Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic ?-hydroxybutyrate or D-?-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic ?-hydroxybutyrate or D-?-hydroxybutyrate, esters of D-?-hydroxybutyrate, oligomers of D-?-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject.

Abstract: The invention is a cap for a pathogen sample tube, the tube having an open end and the cap being configured to secure the open end of the tube to prevent spillage of any sample stored in the tube. The cap includes a first pierceable protective film section configured to enable an automated pipette or other sample withdrawal system to pierce the protective film section and to aspirate at least some of the sample. The cap also includes a second pierceable protective film section lying underneath the first pierceable protective film section; the film sections are separated by an air gap, that is approximately 2 mm in depth. The film sections are made from a thin aluminium foil that is approximately 25 microns thick, with a thin lacquer coating on its upper side and a co-extrusion coating, such as a polymer coating, on the lower side.

Abstract: Embodiments of the present invention are directed to processes for the production of (R)-3-hydroxybutyl (R)-3-hydroxybyrate. Poly (R)-3-hydroxybyrate is transesterified with an alcohol, to form a first ester portion and a second ester portion. The first ester portion is reduced to the diol to form a diol portion and the diol portion is reacted with the second ester portion to produce (R)-3-hydroxybutyl (R)-3-hydroxybyrate.